Manipal further sweetens offer for Fortis Healthcare

NEW DELHI: The Manipal-TPG combine today revised the offer for Fortis Healthcare by committing to invest in the cash-strapped firm at Rs 180 per share, thus increasing the valuation to Rs 9,403 crore.

In a regulatory filing, Fortis Healthcare Ltd (FHL) said it has received revised offer from Manipal and TPG with a proposal to invest in the company, while making public a letter sent by Manipal Health Enterprises Pvt Ltd (MHEPL) to the Fortis board.

Having lost out to the Munjal-Burmans combine last week, Manipal-TPG which was the first to make a offer to Fortis Healthcare Ltd, said that for purposes of the merger, a value of Rs 9,403 crore shall be attributed to FHL under its revised offer.

On the other hand, a value of Rs 6,070 crore shall be attributed to MHEPL as had been originally determined by the independent valuers of for the purpose of the transaction, it said in the letter.

“The preferential allotment shall be undertaken at a price of Rs 180 per share. For purposes of the merger, a value of Rs 9,403 crore shall be attributed to FHL and a value of Rs 6,070 crore shall be attributed to MHEPL as had been originally determined by the independent valuers of for the purpose of the transaction.

  • Related Posts

    Yashoda Medicity’s Medical Tourism Footprint widens with Republic of Kazakhstan on Board

    MOU signed for Patient Referrals, Tele-Consultations and Specialist Healthcare Collaboration Delhi NCR: Unveiled not long ago, Yashoda Medcity’s reputation as being best in class healthcare facility in Delhi NCR has…

    Liver enters FATal Straits in India, AIIMS Experts red flag

    In first for India, World Congress of Gastroenterology comes calling to asses GI disease burden New Delhi: As global and national burden of digestive diseases reach a critical crossroads, World…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre